FDA
-
-
-
-
-
-
-
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
-
-
-
-
-
-
-
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
Aura Biosciences (AURA) PT Raised to $25 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Aura Biosciences (AURA)
-
-
-
-
-
-
-
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
-
-
-
-
-
-
-
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
-
328,367 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

